TGFB1 and hepatocellular carcinoma: Clinical observations showed that HQZX compound containing XCHT combined with TACE in the treatment of patients with intermediate and advanced HCC resulted in prolonged median survival and may improve patients'quality of life by modulating IL-17 and TGF-β pathways [156, 163].